Evidence map›Paper›PMID 38375161›Full record

ArticlePreventive medicine reports2024

Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trial.

Mary Pegington, Hui Zhen Tam, Adam Brentnall, Ivana Sestak, Judith Adams, Glen M Blake, D Gareth Evans, Anthony Howell, Jack Cuzick, Michelle Harvie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Preventive medicine reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mary PegingtonThe Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Hui Zhen TamCentre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, UK.
Adam BrentnallCentre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, UK.
Ivana SestakCentre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, UK.
Judith AdamsCentre for Imaging Sciences, University of Manchester, Manchester, UK.
Glen M BlakeSchool of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
D Gareth EvansThe Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Anthony HowellThe Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Jack CuzickCentre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, UK.
Michelle HarvieThe Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Uptake to anastrozole for breast cancer prevention is low, partly due to women's concerns about side effects including gains in weight and specifically gains in body fat. Previous evidence does not link anastrozole with gains in weight, but there is a lack of data on any effects on body composition i.e. changes in fat and fat free mass. Here we assess association of anastrozole with body composition changes in a prospective sub-study from the second international breast intervention trial (IBIS-II). Methods: Participants had DXA scans at baseline and for five years of anastrozole/placebo and beyond (between March 2004 and September 2017. Primary outcomes were changes in body weight, body fat and fat free mass at 9-18 months. A linear model was used to estimate the size of a differential effect in these outcomes by randomised treatment allocation adjusted for baseline value and time since last scan, age, 10-year breast cancer risk, smoking and HRT status. Results: 203 postmenopausal women were recruited (n = 95 anastrozole, n = 108 placebo), mean age 58 years (SD = 5.4), BMI 28.0 kg/m Conclusions: There is unlikely to be a clinically significant change to body composition with anastrozole for breast cancer prevention.

Identifiers

PMID38375161
PMCPMC10874867

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.